BSX Boston Scientific
FY2025 10-K
Boston Scientific (BSX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 17, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Medical devices portfolio across Endoscopy, Urology, Neuromodulation, MedSurg, and Cardiovascular segments
- • Cardiovascular strategic shift: Discontinued ACURATE Neo2/Prime Aortic Valve sales globally, ceased pursuit of FDA and other approvals in 2025
Management Discussion & Analysis
- • No revenue, profitability, segment, or cash flow data disclosed in provided MD&A section
- • Management implementing new global ERP affecting internal controls, phased rollout began August 2025 in EMEA
Risk Factors
- • Leverage ratio maximum 4.50x as of December 31, 2025, up from 3.75x pre-Axonics acquisition in November 2024
- • Total debt $11.436B at end of 2025, up from $10.746B in 2024, fixed-rate debt $11.393B versus variable $43M
Financial SummaryXBRL
Revenue
$20.1B
Net Income
$2.9B
Gross Margin
69.0%
Operating Margin
18.0%
Net Margin
14.4%
ROE
12.0%
Total Assets
$43.7B
EPS (Diluted)
$1.94
Operating Cash Flow
$4.5B
Source: XBRL data from Boston Scientific FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Boston Scientific
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.